In 2017 Vironova was invited by the FDA to participate in developing a standard for electron microscopy of liposomes. The standard, produced by the ASTM International, is now accepted and published. It is entitled: ASTM WK54615 “New Guide for Standard Practice for Performing Electron Cryo-Microscopy of Liposomes”
This week you can read an article entitled “Putting viral clearance capabilities to the test” on Biopharm International with contributions by Gustav Gilljam, client project manager at Vironova Biosafety. He describes the key elements in planning virus clearance validation and the article as a whole gives a thorough overview of the scope and challenges of this work.
This week Vironova was at BPI Amsterdam with a booth and presentation. In the cell and gene therapy industry there is clearly an increasing demand for fast, reliable, and cost efficient solutions for viral vector manufacturing. Our presentation generated lots of interest and engagement. Several Big Pharma and biotech companies referred to Vironova as helping them with powerful analytical data in characterization of gene therapy vectors. We were inundated with great contacts at our booth!
Our latest webinar is now available on-demand. Josefina Nilsson and Martin Ryner present “Automated Analysis of Purity and Packaging of Gene Therapy Vectors and VLPs Using Transmission Electron Microscopy (TEM). The webinar ran live on 11th April, with over 200 people participating. Click on this news to access the webinar.”
We have published an extensive article on The Cell Culture Dish. It covers the use of MiniTEM for assessing viral particle quality and features Mathieu Colomb-Delsuc, PhD, our senior scientist in Electron microscopy. You can read an introduction to electron microscopy in biomanufacturing, an interview with Mathieu and watch a recorded webinar, all in the same place.
The Swedish Board for Accreditation and Conformity Assessment (SWEDAC) performed a full inspection and study audit on December 20th 2017 in which Vironova Biosafety was found to operate in compliance with the principles of Good Laboratory Practice as established by the OECD and the European Community. It is specially gratifying that the GLP certificate was issued with no remarks.
We’re very pleased to announce that our patent "A method for quantification of purity of sub-visible particle samples" has now passed the PCT (international patent search/control phase) and will enter national phases early next year.
The event at Cell & Gene Therapy in Amsterdam this week was a successful showcase for MiniTEM. Apart from our own activities at our booth and a presentation in the main program we also received excellent testimonials from Hanna Lesch, Research and Development Director at Finvector.
The Royal Swedish Academy of Engineering Sciences (Kungl. Ingenjörsvetenskapsakademien, IVA), Business Executives Council met on the 29th November for their annual meeting at which we are proud to announce that Vironova’s CEO, Mohammed Homman was elected onto the Board.
We are proud to announce that Vironova has been awarded funding for a two-year research project entitled “Interactive visualization tools for verification and improvement of deep neural network predictions.”
A report entitled “State of the global biomanufacturing and bioprocessing industry 2017” was published in September 2017 by William Reed’s BioPharma-Reporter. The report is based on a state-of-the-industry survey, answered by more than 350 people, covering topics such as current bioprocessing challenges, investment and capacity, cell lines and disposable technologies.
Vironova has published a new article on BioProcess International today together with our friends at FinVector Vision Therapies Oy, Finland. It's a detailed explanation of how MiniTEM can be used for gene therapy applications and well worth a read.
Slides with audio recording of the presentation by Mathieu Colomb-Delsuc, Senior Scientist Vironova. Now available on demand.
Deloitte’s Sweden Technology Fast 50 is a ranking of Sweden's 50 fastest growing technology companies, based on growth in net sales over the past four years. The rankings include both public and private companies, covering all types of technology, from the Internet to computers to life sciences. Technology Fast 50 was founded in 1995 in the United States, and in Sweden the fastest growing technology companies have been ranked since 2004.
In this webinar we will show how MiniTEM can provide powerful data where traditional assays have limitations.
At the recently held BioProcess International Conference in Boston many good contacts were made and many interesting discussions were had. But perhaps most satisfying was the quality of the meetings and the frequency with which people said they already knew about Vironova’s offering and wanted more detailed information.
The MiniTEM system is rapidly making inroads into the material science sector, due to its unique advantages and unmatched capabilities for easy, rapid and cost-effective measurements.
This week we’re in Boston. Come and meet us!
We have a Technology Workshop with Mathieu Colomb-Delsuc at 11:50 Tuesday Sept 26th.
We are looking for a Business Development Manager North America to join our sales team. You will be working with direct sales of Vironova’s products and services, with a strong focus on the recently launched MiniTEM ™ system.
We are looking for an Account Manager Europe to join our sales team. You will be working with direct sales of Vironova’s products and services, with a strong focus on the recently launched MiniTEM ™ system.
On Thursday and Friday this week Vironova’s CTO, Ida-Maria Sintorn, will participate in the 8th Glienicke Workshop on "Electron Microscopy in Infectious Diseases - Diagnostics and Research" at the Robert Koch Institute in Berlin. Ida-Maria has been invited to present MiniTEM as a novel instrument in this field and she’ll talk about up-coming features to customize MiniTEM for analysis of pathology samples.
The conference Advanced Concepts for Intelligent Vision Systems (Acivs) 2017 in Belgium on 18-21 September focuses on techniques for building adaptive, intelligent, safe and secure imaging systems. Submissions are required to be original and high-quality work, from basic research to pre-industrial application.
An interview with our CEO, Mohammed Homman, has just been published in Genetic Engineering and Biotechnology News. Read about how Vironova started and the future of transmission electron microscopy.
As a Gold sponsor of the Swedish American Life Science Summit in Stockholm, Vironova was in good company last week.
Vironova will be represented by our CTO, Ida-Maria Sintorn and Senior scientist, image analysis Patrik Malm. You can find us on Wednesday 23/8 14-16 in the foyer. Our poster is IM3.P003: Automatic sample screening and particle analysis using MiniTEM.
It’s been a busy time lately for the Vironova team giving talks and attending conferences. Our very own Martin Ryner has recently held a presentation at a breakfast meeting organized by Stockholm Science City and STING. The meeting title was “Artificial intelligence in health – a data driven revolution.” This resonates well with what Vironova is striving for in helping to make virus image analysis accessible, cost-effective and objective.
Biological drugs hold tremendous potential but are a major challenge to develop. New analytical methods will be needed, including transmission electron microscopy which Vironova is making accessible for the development and quality control processes in drug development.
Vironova is the leader of the research project: “A smart and easy platform to facilitate ultrastructural pathologic diagnoses.” Through our CTO, Ida-Maria Sintorn, PhD, Vironova has the role of project leader as well as scientific contributor.
Our goal is to adapt MiniTEM™ for simplifying and automating image acquisition, processing and report generation.
A satisfied and happy Vironova team returned from the BPI trade show in Amsterdam last week.
Don’t miss our talk at BPI European Summit: Automated characterization of gene therapy vectors, VLPs and whole viruses. By Josefina Nilsson, head of EM services. April 25, at 15.00 in the vaccine manufacturing stream. A case study how integrity and purity of Adenoassociated virus (AAV) and Adenovirus particles can accurately be measured automatically by using MiniTEM™.
Josefina has extensive experience of characterization of nano-scaled sub-visible particles as a service provider since ten years to the biopharmaceutical industry, from early development to final manufacturing.
Vironova will host a webinar “Automated purity and integrity check of gene therapy vectors” on April 6 at 3 pm CET.
A full-day event including live demo of MiniTEM and presentations showing how to go from manual to automated virus particle characterization attracted more than 10 different companies located in Europe. Invited speaker Vesa Turkki, Senior Scientist at FinVector Vision Therapies gave a presentation explaining how MiniTEM helps them to link product understanding to process control during development of gene therapy products.
Vironova has established a growing number of global customers in the highly-regulated and quality demanding pharmaceutical industry, who focus on drug/gene delivery and vaccine development. Currently 7 of the 10 largest biopharmaceutical companies are clients to Vironova.
Vironova has now filed a patent for quantitative analysis of viral vector content using cryoTEM, a method that has already triggered plenty of interest amongst our customers.
Time: 3:00pm London, 10:00am New York
2016 saw Mikael Wik appointed as new CEO and a record sales performance that beat all previous years, with a turnover of 25,9 MSEK. The two founders and previous leaders since 1985 continue to be active in sales and business development.
Everybody with a need to speed up process development or secure final product quality of virus particle based therapeutics should attend this seminar. The event offers an opportunity to learn about Vironova’s solutions for nanoparticle characterization directly from the developers and experts.
Vironova AB is once again a participant in a cutting-edge research program, this time in a Big Data and Computational Science entitled program “Hierarchical Analysis of Temporal and Spatial Image Data.”
In one of the fastest growing drug development areas today, nano-particles (for example liposomes), visible using electron microscopy, are used to deliver drugs to their exact targets in the body.
At Vironova we are proud about being part of this new FoRmulaEx centre that has been recognized by SSF to meet the highest international scientific standards. The FoRmulaEx centre will develop methods for efficient and robust delivery of complex, oligonucleotide drugs. Our participation is an endorsement of our leading position in enabling electron microscopy technologies that help to speed up product development and secure final product quality in the pharmaceutical industry.
Ask the Expert article "Reveal Information That Provides Insights” in the December issue of BioProcess International.
The article features Josefina Nilsson and Gustaf Kylberg who present the benefits of using MiniTEM in purity analysis during process development.
Shareholders of Vironova AB (publ), are hereby invited to the extra general meeting on Wednesday, December 21, 2016 at. 15:00 at company headquarters, Gävlegatan 22, exit C, 113 30 Stockholm, Sweden
Eva is recognized by DI Digital as one of Sweden’s most powerful tech-investors. She has a long career in the financial sector. After 30 years in the industry, as an entrepreneur and an employee at Investor, she completed her operative career as CEO and Chairman of Erik Penser Bank in 2008.
Mohammed receives the prize as a recognition for his open minded, energetic and solution oriented approach that has resulted in positioning Vironova as a highly versatile and multicultural working place and a company that attracts top talents that delivers disruptive technology for sub-visible particle characterization. The jury describes Mohammed Homman as an important role model that proves the potential of having an open and versatile Swedish society.
Vironova is growing. There is no room for us anymore in our current place. Every week there are new additions to our team and our EM facilities are expanding in order to meet the growing demand for services as well as to be able to store and service our MiniTEM systems.
Date: October 19-21 in Prague
A Medical Workshop where Ida-Maria Sintorn presented “MiniTEM- a Broad Range Viral Pathogen Detection System” .
Date: October 19
Time: 11:00am - 11:15am EDT
The workshop “Reveal Information that Gives Insights – New Approaches to Sub-Visible Particle Characterization” by Gustaf together with Josefina Nilsson, head of EM services gave an in depth presentation on how to automatically acquire an accurate purity metrics as well as visual proof of Adenovirus particle samples at different steps in the purification process.
The new MiniTEM low voltage transmission electron microscope system was introduced for the first time to a larger audience at the Boston Biotech Week.
We are looking for a Field Engineer to join our Instruments group who will work with technical sales, installation, technical support and troubleshooting with our customers.
Dr. Josefina Nilsson, Head of EM services and Dr. Gustaf Kylberg, Product Manager MiniTEM, Vironova AB
Josefina Nilsson, head of Vironova EM services, is featured in the editorial article in the June issue of Bioprocess International where she describes how electron microscopy and image analysis performed by Vironova provide all the structural information needed for effective and high-quality research, development and manufacturing of gene and drug delivery systems.
The Vironova MiniTEM event in conjunction to the BioSpring Europe Stockholm meeting attracted more than 40 carefully selected VIP guests in leading positions from the Life Science industry. The first manufactured series of the MiniTEM microscope was presented accompanied by wine tasting in a nice atmosphere at the 33rd floor of the BioSpring conference venue.
The acquisition of NOW is part of a long term plan of Vironova of building a strong technology platform to enable further development of electron microscopy based analysis tools for nanoparticle characterization. Vironova has together with NOW developed a camera specialized for electron microscopy use.
“We are happy to welcome Nina Forsberg, our new marketing strategist, to the Vironova team. Nina brings extensive experience from the Pharmaceutical industry where she has gained a vast experience introducing new products to the Pharmaceutical market,” comments Mohammed Homman, Founder and CEO of Vironova AB.
Nina’s experience from the Pharmaceutical industry includes work at Roche, Amersham and GE Healthcare.
Please fill out the following information with as much detail as you can, in order for us to provide you with an accurate quote as soon as possible.